Mid-weight oncology stocks: The dark horses of cancer research
18 No. of Symbols
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.7723 USD
−67.88 M USD
324.24 M USD
36.80 M
About The Oncology Institute, Inc.
Sector
Industry
CEO
Daniel Virnich
Website
Headquarters
Cerritos
Founded
2007
FIGI
BBG00S5H21H2
The Oncology Institute, Inc. provides cancer care treatment services. It operates through the following business segments: Dispensary, Patient Care, and Clinical Trials and Other. The company was founded in 2007 and is headquartered in Cerritos, CA.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where TOI is featured.
Frequently Asked Questions
The current price of TOI is 0.1322 USD — it has increased by 7.14% in the past 24 hours. Watch The Oncology Institute, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange The Oncology Institute, Inc. stocks are traded under the ticker TOI.
TOI stock has fallen by −30.10% compared to the previous week, the month change is a −45.62% fall, over the last year The Oncology Institute, Inc. has showed a −93.96% decrease.
TOI stock is 40.62% volatile and has beta coefficient of 0.37. Track The Oncology Institute, Inc. stock price on the chart and check out the list of the most volatile stocks — is The Oncology Institute, Inc. there?
Today The Oncology Institute, Inc. has the market capitalization of 13.60 M, it has decreased by −1.69% over the last week.
Yes, you can track The Oncology Institute, Inc. financials in yearly and quarterly reports right on TradingView.
The Oncology Institute, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
TOI earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.07 USD resulting in a −157.14% surprise. The estimated earnings for the next quarter are −0.08 USD per share. See more details about The Oncology Institute, Inc. earnings.
The Oncology Institute, Inc. revenue for the last quarter amounts to 99.90 M USD, despite the estimated figure of 107.54 M USD. In the next quarter, revenue is expected to reach 109.15 M USD.
TOI net income for the last quarter is −13.22 M USD, while the quarter before that showed −12.68 M USD of net income which accounts for −4.29% change. Track more The Oncology Institute, Inc. financial stats to get the full picture.
No, TOI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 800.00 employees. See our rating of the largest employees — is The Oncology Institute, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. The Oncology Institute, Inc. EBITDA is −57.32 M USD, and current EBITDA margin is −16.70%. See more stats in The Oncology Institute, Inc. financial statements.
Like other stocks, TOI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade The Oncology Institute, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So The Oncology Institute, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating The Oncology Institute, Inc. stock shows the sell signal. See more of The Oncology Institute, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.